|
Home
Page
Bella Mira Essential Oil
Supplements
Organic Carrier Oils
Diffusers
Bella Mira Skin Care
Essential Oil Information and Use
Express Order Form
Essential Oil
Singles
Essential Oil
Blends
Essential Oil
Kits
Essential Oil Supplies
Gluten Free Living and Recipes
Thyroid 101
Fibromyalgia 101
PAIN Relief and Information
Detoxification and Digestion Products
Pet Place
Save Your Computer Free Protection
CD's DVD's and Books
3-D Screensavers
Hormone Balance Test New
Improved
Thyroid Function Test
Internal Toxicity Test

Gift Certificates
Link Exchange/Banners
.gif)

Our
Shopping Cart Is:

& FAQ



| |
Osteoporosis Drug Fosamax Doubles Risk of
Life-Threatening Heart Condition 10-16-08
by: David Gutierrez
The widely prescribed osteoporosis drug Fosamax (generic name alendronate)
appears to double women's risk of developing a chronic irregular heartbeat known
as atrial fibrillation, according to a study conducted by researchers from the
University of Washington and published in the Archives of Internal Medicine.
Atrial fibrillation can lead to dizziness, fatigue and momentary loss of
consciousness.
Researchers reviewed data from a long-term study of atrial fibrillation
conducted by a Washington state health care provider, Group Health. Out of 719
women with atrial fibrillation, 6.5 percent had taken the osteoporosis drug at
some point, compared with only 4.1 percent of the women without the heart
condition. This meant that women who had taken Fosamax had an 86 percent higher
risk of atrial fibrillation than women not on the drug, and that Fosamax
accounted for 3 percent of all cases of the disorder.
Ethel Siris, president of the National Osteoporosis Foundation, noted that the
researchers looked at women who had previously taken the drug, not just those
who were currently taking it. This suggests that the drug's effects on the heart
persist even when it is no longer being taken.
The current study was inspired by a recent re-analysis of a 1997 study, finding
that the osteoporosis drug zoledronate (marketed as Aclasta, Reclast, Zomera and
Zometa), which is taken intravenously, increased the risk of severe atrial
fibrillation compared to a placebo.
Both zoledronate and alendronate are in the same drug family, and thus would be
expected to have similar effects on the body. However, Fosamax is the only drug
that is known to be able to build bone mass in women at risk of osteoporosis,
and is believed to reduce the risk of hip fractures by 63 percent.
Lead author Susan Heckbert cautioned that women should not stop taking
osteoporosis medications without first consulting their physician.
Search Heart
Search Osteoporosis
Search Bone
|